Orthopoxvirus antigen protein, composition and device for diagnosing orthopoxvirus antibodies comprising the same
The antigen-antigen sandwich immunoassay using specific orthopoxvirus protein combinations addresses the limitations of existing methods by enhancing sensitivity and specificity in diagnosing orthopoxvirus antibodies, achieving improved diagnostic accuracy.
Patent Information
- Application Number
- KR1020240100136
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-07-29
AI Technical Summary
Existing diagnostic methods for orthopoxvirus antibodies lack sensitivity and specificity, particularly in distinguishing between positive and negative samples, necessitating the development of a rapid and accurate diagnostic tool for orthopoxvirus infections.
An antigen-antigen sandwich immunoassay using specific combinations of orthopoxvirus membrane and surface proteins, such as B5R and A33R, to enhance the detection of orthopoxvirus antibodies, with a preferred weight ratio of 1:9 to 9:1 for optimal results.
The antigen-antigen sandwich immunoassay significantly improves sensitivity and specificity in diagnosing orthopoxvirus antibodies, achieving a signal-to-noise ratio of 10 or higher, distinguishing between positive and negative samples effectively.
Smart Images

Figure 112024082238913-PAT00008_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to an orthofoxvirus antigen protein, a composition for diagnosing orthofoxvirus antibodies containing the same, and an apparatus. Background Technology
[0003] Smallpox is an acute disease characterized by fever, blisters, and pustular pathological skin changes, caused by the smallpox virus. It has a very high mortality rate and once accounted for 10% of all causes of death worldwide, including in Korea; however, in 1979, smallpox was declared eradicated globally. Nevertheless, following the report of a single case of monkeypox in the UK on May 7, 2022, cases of infection have been reported in numerous countries including the United States, Brazil, Spain, France, and Colombia, and interest has recently been growing again as the possibility of the smallpox virus being used as a biological terror weapon has become known.
[0004] In Korea, monkeypox was designated as a Class 2 infectious disease on June 8, 2022, and the crisis level was raised from 'concern' to 'caution' following the final confirmation that a Korean national who visited Germany tested positive for monkeypox in June of the same year. With increased international travel, the possibility of further influx cannot be ruled out, and given the difficulty of diagnosis based solely on clinical symptoms, the role of rapid and accurate laboratory diagnostic testing is crucial for the early detection of monkeypox and the prevention of community spread amidst this unprecedented global epidemic.
[0005] Meanwhile, A17L, A27L, A28L, A33R, B5R, D8L, L1R, and H3 have been reported as vaccinia virus proteins identified as targets of neutralizing antibodies in humans (Non-patent Literature 1).
[0006] Against this background, the inventors have developed an antigen protein for diagnosing (detecting) antibodies specific to Orthopoxvirus using an antigen-antigen sandwich immunoassay utilizing a major antigen protein of vaccinia virus for rapid and accurate diagnosis of Orthopoxvirus antibodies, a composition for diagnosing Orthopoxvirus antibodies containing the same, and an apparatus, and have completed the present invention by demonstrating the efficacy thereof. Prior art literature
[0008] Ahmed SF, Sohail MS, Quadeer AA, McKay MR. Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus. Viruses. 2022 Sep 3;14(9):1960. The problem to be solved
[0009] The objective of the present invention is to provide an orthofoxvirus antigen protein for rapid and accurate diagnosis of orthofoxvirus antibodies and a composition for diagnosing orthofoxvirus antibodies containing the same.
[0010] Another objective of the present invention is to provide a device and kit for diagnosing an orthofoxvirus antibody comprising the orthofoxvirus antigen protein.
[0011] Another objective of the present invention is to provide a method for providing information for diagnosing an orthofoxvirus antibody using the orthofoxvirus antigen protein.
[0012] The problems that the present invention aims to solve are not limited to the problem(s) mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art from the description below. means of solving the problem
[0014] To solve the above problem, the present invention provides an orthophoxvirus antigen protein used in an antigen-antigen sandwich immunoassay for antibody diagnosis, wherein each of the capture antigen and the detection antigen comprises a part or all of an orthophoxvirus membrane protein or a surface protein.
[0015] Each of the above capture antigen and detection antigen may be any one of the antigens comprising part or all of the amino acid sequences of SEQ ID NOs 1 to 5.
[0016] Each of the above capture antigen and detection antigen may include part or all of the amino acid sequence of SEQ ID NO. 3, or each of the capture antigen and detection antigen may include part or all of the amino acid sequence of SEQ ID NO. 5.
[0017] In addition, the present invention provides an orthophoxvirus antigen protein used in an antigen-antigen sandwich immunoassay for antibody diagnosis, wherein each of the capture antigen and the detection antigen comprises two or more combinations among antigens comprising part or all of the amino acid sequences of SEQ ID NOs 1 to 5.
[0018] The above combination may include an antigen comprising part or all of the amino acid sequence of SEQ ID NO. 3.
[0019] The above combination may include an antigen comprising part or all of the amino acid sequence of SEQ ID NO. 5.
[0020] Each of the above capture antigen and detection antigen may include an antigen comprising part or all of the amino acid sequence of SEQ ID NO. 3 and an antigen comprising part or all of the amino acid sequence of SEQ ID NO. 5.
[0021] The above combination may be one in which antigens are mixed in a weight ratio of 1:9 to 9:1.
[0022] The above orthopoxvirus may be a smallpox virus, a vaccinia virus, or a monkeypox virus.
[0023] In addition, the present invention provides a composition for diagnosing orthofox virus antibodies comprising the aforementioned antigen protein.
[0024] In addition, the present invention provides a device for diagnosing orthofox virus antibodies comprising the aforementioned antigen protein.
[0025] The above-mentioned orthofoxvirus antibody diagnostic device may utilize antigen-antigen sandwich analysis.
[0026] The above-described orthofoxvirus antibody diagnostic device may include a capture antigen immobilized on a solid phase and a detection antigen comprising a detectable label.
[0027] The above detection antigen may include any one of a chromogenic enzyme, a luminescent enzyme, a radioactive isotope, a chromopore, a luminescent substance, a fluorescent substance, or a microparticle containing each of these.
[0028] The above-mentioned orthofoxvirus antibody diagnostic device may utilize a lateral flow immunoassay (LFA), an enzyme-linked immunosorbent assay (ELISA), or a chemiluminescence immunoassay (CLIA).
[0029] The above orthopoxvirus may be a smallpox virus, a vaccinia virus, or a monkeypox virus.
[0030] In addition, the present invention provides a diagnostic kit for orthofox virus antibodies comprising the aforementioned antigen protein.
[0031] In addition, the present invention provides a method for providing information for diagnosing an orthofox virus antibody, comprising (a) contacting a biological sample isolated from an individual with the antigen protein of claim 1, and (b) confirming an antigen-antibody reaction between the antigen protein and the antibody in the biological sample.
[0032] In step (b) above, one part of the antibody may react with the capture antigen and another part of the antibody may react with the detection antigen. Effects of the invention
[0034] According to the Orthopoxvirus antigen protein used in the antigen-antigen sandwich immunoassay for antibody diagnosis according to the present invention, the composition and apparatus for diagnosing Orthopox antibodies containing the same have the effect of improving sensitivity and specificity compared to conventional antibody diagnostic methods.
[0035] The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description of the invention or the claims. Brief explanation of the drawing
[0037] Figure 1 is a graph showing the S / N ratio according to an antigen (capture)-antigen (detector) pair according to one embodiment of the present invention. Figure 2 is a graph showing the S / N ratio according to the capture-detector pairs A33R-A33R, A33R+B5R-A33R+B5R, and B5R-B5R according to one embodiment of the present invention. Figure 3 is a graph showing the S / N ratio according to the mixing ratio (line dotting) in the combination of A33R and B5R antigens according to one embodiment of the present invention. Figure 4 is a graph showing the S / N ratio according to the mixing ratio (conjugate) in the combination of A33R and B5R antigens according to one embodiment of the present invention. Figure 5 is a graph showing sensitivity according to specificity when using a conventional class capture (indirect) immunoassay method according to one embodiment of the present invention. Figure 6 is a graph showing sensitivity according to specificity when using the antigen-antigen sandwich analysis method according to one embodiment of the present invention. Specific details for implementing the invention
[0038] It should be noted that in the following description, only the parts necessary for understanding the embodiments of the present invention are described, and the description of other parts will be omitted to the extent that it does not detract from the gist of the present invention.
[0039] The terms and words used in this specification and claims described below shall not be interpreted as being limited to their ordinary or dictionary meanings, but shall be interpreted in a meaning and concept consistent with the technical spirit of the invention, based on the principle that the inventor may appropriately define the concept of the terms to best describe his invention.
[0040] Therefore, the embodiments described in this specification and the configurations illustrated in the drawings are merely preferred embodiments of the present invention and do not represent all technical concepts of the present invention; thus, it should be understood that various equivalents and modifications that can replace them may exist at the time of filing this application.
[0041] The present invention will be described in detail below.
[0042] As mentioned above, with monkeypox infection cases occurring simultaneously worldwide since 2022, the possibility of the smallpox virus being used as a biological terror weapon is emerging, making it necessary to develop rapid and accurate diagnostic devices / kits in preparation. In this invention, an antigen protein for diagnosing (detecting) antibodies specific to Orthopoxvirus using an antigen-antigen sandwich immunoassay method by utilizing the major antigen protein of the vaccinia virus, which has been identified as a target of neutralizing antibodies in humans, as well as a composition and device for diagnosing Orthopoxvirus antibodies containing the same, were developed and their performance was verified.
[0044] Orthofoxvirus antigen protein
[0045] The present invention provides an orthophoxvirus antigen protein used in an antigen-antigen sandwich immunoassay for antibody diagnosis, wherein each of the capture antigen and the detection antigen comprises a part or all of an orthophoxvirus membrane protein or a surface protein. The membrane protein of the virus refers to a constituent protein of an outer or inner membrane or envelope surrounding the virus, and the surface protein of the virus refers to a protein that is bound to the membrane protein and protrudes outward.
[0046] Conventionally, class capture immunoassays have been used for antibody diagnosis, but the present invention is characterized by using an antigen-antigen sandwich immunoassay.
[0047] In the phrase “the antigen comprises part or all of a protein or amino acid sequence” of the present invention, the part of the protein or amino acid sequence may be an antigenic determinant, an antibody binding site, or an antibody binding fragment, i.e., an epitope.
[0048] When detecting vaccinia proteins L1R, B5R, A27L, and A33R, respectively, as antigens for diagnosing orthofox virus antibodies using a conventional class capture immunoassay, limitations in sensitivity and specificity were observed (Table 2). A conventional class capture immunoassay, also known as an indirect immunoassay, is a method in which antibodies (non-specific antibodies + specific antibodies) in a sample bind to a fixed immunoglobulin-binding protein (anti-human IgG or IgM), and the antigen labeled on the specific antibody (anti-viral human IgG or IgM) among these antibodies reacts specifically to detect the antigen, or conversely, the specific antibody in the sample binds to a fixed specific antigen, and the antigen is detected by the specific reaction of these antibodies to the labeled immunoglobulin-binding protein (anti-human IgG or IgM).
[0049] Accordingly, the present invention provides an orthofoxvirus antigen protein used in an antigen-antigen sandwich immunoassay. The antigen-antigen sandwich immunoassay is also referred to as a double antigen sandwich immunoassay, in which a portion of an antibody in a sample specifically reacts with a capture antigen and another portion of the antibody specifically reacts with a detection antigen to detect the antigen. The capture antigen may be immobilized in a solid phase, and the detection antigen may be labeled with a detectable substance.
[0050] The above antigen protein may be any one of the antigens in which the capture antigen and the detection antigen, respectively, in the antigen-antigen sandwich immunoassay include part or all of the amino acid sequences of SEQ ID NOs 1 to 5. Part of the amino acid sequence may be an antigenic determinant, an antibody binding site, or an antibody binding fragment, i.e., an epitope. Although the specific embodiment of the present invention was performed using an antigen including all of the amino acid sequences of SEQ ID NOs 1 to 5, it is obvious to a person skilled in the art that if an antigen including all of the amino acid sequences exhibits efficacy in the art, an antigen including only a part thereof, such as an antigenic determinant (epitope), also exhibits efficacy.
[0051] In addition, the antigen proteins may each include part or all of the amino acid sequence of SEQ ID NO. 3 in the antigen-antigen sandwich immunoassay, or each include part or all of the amino acid sequence of SEQ ID NO. 5. Specifically, when the antigen proteins in the antigen-antigen sandwich immunoassay are denoted as capture antigen-detection antigen pairs, they may be antigen proteins including vaccinia proteins L1R-L1R, D8L-D8L, A33R-A33R, A27L-A27L, and B5R-B5R, respectively, and in particular, they may be antigen proteins including B5R-B5R and A33R-A33R, respectively.
[0052] In a specific embodiment of the present invention, L1R, B5R, A27L, A33R, and D8L were used as capture antigens, and L1R, B5R, A27L, and A33R were used as detection antigens for each of the capture antigens. As a result, it was confirmed that the S / N ratio of the B5R-B5R and A33R-A33R pairs was 10 or higher, making it possible to distinguish between positive and negative (Fig. 1, Table 3).
[0053] In addition, the present invention provides an orthophoxvirus antigen protein used in an antigen-antigen sandwich immunoassay for antibody diagnosis, wherein each of the capture antigen and the detection antigen comprises two or more combinations among antigens comprising part or all of the amino acid sequences of SEQ ID NOs 1 to 5.
[0054] The above combination may include an antigen comprising part or all of the amino acid sequence of SEQ ID NO. 3.
[0055] The above combination may include an antigen comprising part or all of the amino acid sequence of SEQ ID NO. 5.
[0056] In addition, each of the above capture antigen and detection antigen may include an antigen comprising part or all of the amino acid sequence of SEQ ID NO. 3 and an antigen comprising part or all of the amino acid sequence of SEQ ID NO. 5.
[0057] The amino acid sequences of SEQ ID NOs 1 to 5 above are major antigen proteins of vaccinia virus identified as targets of neutralizing antibodies in humans, wherein the amino acid sequence of SEQ ID NO 1 is the amino acid sequence constituting the vaccinia virus L1R protein (IMV membrane protein), the amino acid sequence of SEQ ID NO 2 is the amino acid sequence constituting the vaccinia virus D8L protein (IMV membrane protein), the amino acid sequence of SEQ ID NO 3 is the amino acid sequence constituting the vaccinia virus A33R protein (EEV membrane glycoprotein), the amino acid sequence of SEQ ID NO 4 is the amino acid sequence constituting the vaccinia virus A27L protein (IMV surface protein), and the amino acid sequence of SEQ ID NO 5 is the amino acid sequence constituting the vaccinia virus B5R protein (EEV type-I membrane glycoprotein). The amino acid sequences of SEQ ID NOs 1 to 4 above are shown in Table 1 below.
[0058]
[0059] In a specific embodiment of the present invention, it was confirmed that the detection signal is higher when the antigens selected as capture antigens and detection antigens are used in combination rather than individually. In particular, when the B5R antigen and the A33R antigen were used in combination, the detection signal was generally higher in various positive samples (Fig. 2, Table 4).
[0060] The antigens used for each of the above capture antigens and detection antigens may be a mixture of the antigens in a weight ratio of 1:9 to 9:1. Additionally, preferably, the antigen proteins may be a mixture of the antigen proteins in a weight ratio of 2:8 to 8:2, 3:7 to 7:3, 4:6 to 6:4, or 5:5.
[0061] In a specific embodiment of the present invention, B5R antigen and A33R antigen were mixed and used as the capture antigen and detection antigen, respectively, in a weight ratio of 10:0 to 0:10. As a result, when the weight ratio of A33R:B5R of the capture antigen and detection antigen, respectively, was in the range of 1:9 to 9:1, the detection signal appeared above a certain level, and in particular, an even reaction was observed in the range of the A33R:B5R ratio of 5:5 to 2:8 (Fig. 3-4, Table 4-5).
[0062] The above orthopoxvirus may be a smallpox virus, a vaccinia virus, or a monkeypox virus.
[0064] Composition for diagnosing orthofoxvirus antibodies
[0065] The present invention provides a composition for diagnosing an orthofoxvirus antibody comprising the aforementioned orthofoxvirus antigen protein.
[0066] In the present invention, the term "diagnosis" means confirming the presence or absence of antibodies against Orthopoxvirus by detecting specific antibodies containing IgG or IgM in a biological sample isolated from an individual. If the antibody diagnostic test result according to the present invention is positive, it indicates that antibodies against Orthopoxvirus (regardless of type, such as G, M, A, etc.) are present in the body. This implies a history of infection with Orthopoxvirus.
[0067] In a specific embodiment of the present invention, it was confirmed that vaccinia virus-specific antibodies can be effectively detected through an antigen-antibody reaction with antibodies in a sample by using a composition containing the aforementioned antigen protein in an antigen-antigen sandwich immunoassay.
[0068] The composition of the present invention may include a buffer or reaction solution that stably maintains the structure or physiological activity of the antigen protein. Additionally, to maintain stability, it may be provided in a powder state, dissolved in a suitable buffer, or maintained at a constant temperature such as 4°C.
[0070] Orthofoxvirus antibody diagnostic device or kit
[0071] The present invention provides an antibody diagnostic device or kit comprising the aforementioned orthofox virus antigen protein.
[0072] The antibody diagnostic device according to the present invention refers to a diagnostic device that includes an antigen against vaccinia virus as an active ingredient and provides information regarding whether or not orthofoxvirus antibodies have been produced and the history of orthofoxvirus infection, and is not limited to any form that can confirm the presence or absence of IgG antibodies from a biological sample.
[0073] A specific example of an antibody diagnostic device according to the present invention is an antibody diagnostic kit. The kit of the present invention may take the form of a bottle, tub, sachet, envelope, tube, ampoule, etc., and may be formed partially or wholly from plastic, glass, paper, foil, wax, etc. The container may be equipped with a cap that is part thereof or can be attached to the container by mechanical, adhesive, or other means and is fully or partially detachable. Additionally, the container may be equipped with a stopper that allows access to the contents by a syringe needle. The antibody diagnostic device described below includes an antibody diagnostic kit.
[0074] The above antibody diagnostic device may utilize an antigen-antigen sandwich immunoassay.
[0075] The above antigen-antigen sandwich immunoassay method may comprise a capture antigen immobilized on a solid phase and a detection antigen comprising a detectable label, and each of the capture antigen and the detection antigen may comprise a specific antigen, and the specific antigen may be the aforementioned orthofoxvirus antigen protein.
[0076] The above-mentioned capture antigen is immobilized on a solid phase, and the solid phase may be in the form of a membrane or a plate. One or more specific antigens may be coated on this solid phase, either alone or in combination, and specifically, the specific antigens may be coated with the aforementioned orthofox virus antigen proteins, either alone or in combination.
[0077] The above detection antigen may include a substance that generates a detectable signal by binding a labeling substance to a specific antigen. Specifically, the labeling substance may include a labeling substance such as a chromogenic enzyme, a luminescent enzyme, a radioisotope, a chromopore, a luminescent substance, a fluorescent substance, and a microparticle containing each of these, conjugated to the antigen, and the form in which such a detectable labeling substance is bound to the antigen is called a 'conjugate'. The above detection antigen is formed by binding one or more specific antigens, either alone or in combination, to the detectable labeling substance as described above; specifically, this specific antigen may be formed by binding the aforementioned orthofox virus antigen proteins, either alone or in combination.
[0078] The above-mentioned chromogenic enzyme or luminescent enzyme includes, but is not limited to, peroxidase, alkaline phosphatase, luciferase, etc. The above-mentioned radioactive isotope is 124 I, 125 I, 111 In,99 mTc, 32 P or 35 S is included, but not limited thereto. The above-mentioned luminescent or fluorescent material includes lanthanide-based fluorescent materials such as FITC, RITC, rhodamine, Texas Red, fluorescein, phycoerythrin, Europium, etc., or quantum dots, but is not limited thereto.
[0079] The detection antigen containing the above-mentioned detectable label can be detected using a conventionally known detection method for each label. For example, when using the fluorescent signal FITC as a label, a method can be used to measure the fluorescence intensity for each antigen protein concentration at the maximum wavelength (Excitation: 495 nm, Emission: 520 nm) of FITC linked to the antigen protein using a fluorometer.
[0080] The above antibody diagnostic device may use a lateral flow immunoassay (LFA), an enzyme-linked immunosorbent assay (ELISA), or a chemiluminescence immunoassay (CLIA), or use an application or modification thereof.
[0081] The above orthopoxvirus may be a smallpox virus, a vaccinia virus, or a monkeypox virus.
[0082] The antibody diagnostic device of the present invention may include a buffer or reaction solution that stably maintains the structure or physiological activity of an antigen protein. In addition, to maintain stability, it may be provided in a powder state, in a state dissolved in a suitable buffer, or in a state maintained at a constant temperature such as 4°C.
[0084] Method of providing information for orthofoxvirus antibody diagnosis
[0085] The present invention provides a method for providing information for diagnosing an orthofoxvirus antibody, comprising (a) contacting a biological sample isolated from an individual with the aforementioned orthofoxvirus antigen protein, and (b) confirming an antigen-antibody reaction between the antigen protein and an antibody in the biological sample.
[0086] The above biological sample refers to a sample of a subject for which it is necessary to confirm the presence of an orthopoxvirus or specific antibodies produced by it. Specifically, it may be isolated from one or more selected from the group consisting of blood, plasma, serum, lymph, urine, tears, synovial fluid, saliva, wound fluid, and cerebrospinal fluid, and, for example, may be isolated from serum, but is not limited thereto.
[0087] The method for providing information for diagnosing orthofox virus antibodies according to the present invention is It may involve using antigen-antigen sandwich analysis.
[0088] In step (a) above, contacting the biological sample with the antigen protein may involve contacting the biological sample with the capture antigen and the detection antigen. More specifically, step (a) may involve contacting the biological sample with the capture antigen immobilized on a solid surface, and then contacting the detection antigen (a conjugate in which the label and the antigen are conjugated) with it. Here, contact may be achieved by mixing the biological sample and the detection antigen and introducing them simultaneously into the capture antigen, or by introducing them separately and sequentially. Each of the capture antigen and the detection antigen may contain a specific antigen, and this specific antigen may be the aforementioned orthofoxvirus antigen protein.
[0089] Step (b) above involves confirming the antigen-antibody reaction between the antigen protein and the antibody in the biological sample, and confirming the antigen-antibody reaction between the capture antigen and the detection antigen, respectively, and the antibody in the biological sample. Specifically, this may involve a portion of the antibody reacting with the capture antigen and another portion of the antibody reacting with the detection antigen.
[0090] Step (b) above may include confirming a detection signal from a label included in the detection antigen when performing the antigen-antibody reaction. If the label is a chromogenic enzyme, a chromogenic step may be included in which the sample that has undergone the contact step of (a) is brought into contact with the chromogenic enzyme. At this time, the chromogenic enzyme may bind to an antibody against the specific antigen contacted with the sample to produce a chromogenic reaction.
[0091] If no detection signal (color development, luminescence, fluorescence, etc.) appears in step (b) above, it means that no antigen-antibody reaction occurred, which implies that there are no antibodies against the specific antigen in the sample. In other words, if no detection signal appears, it means that there are no antibodies in the sample.
[0093] Examples
[0094] The present invention will be explained in detail below through examples and experimental examples. However, the following examples and experimental examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples and experimental examples.
[0096] Example 1: Confirmation of Specificity and Sensitivity of Class Capture Immunoassay
[0097] To confirm the specificity and sensitivity when diagnosing antibodies against orthofoxvirus using a conventional class capture immunoassay (or indirect immunoassay), the following was performed.
[0098] 1) Human Anti IgM and IgG antibodies are immobilized on a membrane at a concentration of 1 mg / mL using a dispenser.
[0099] 2) Prepare a gold or fluorescent bead conjugate by conjugating viral antigens L1R, B5R, A27L, and A33R at a concentration of 100 µg / mL.
[0100] 3) Mix equal amounts of each virus antigen conjugate and apply the mixture to the conjugate pad so that the amount is 0.1 µg per test.
[0101] 4) Attach a conjugate pad and a sample pad to a membrane card dispensed with antibodies, then cut it into a uniform size to prepare it in the form of a strip.
[0102] 5) After assembling the strip into the cassette, load 5 uL of positive or negative sample onto the bottom of the membrane, then drop 85 uL of development buffer into the sample inlet of the test cassette.
[0103] 6) 15 minutes after the drop, the result was measured using Sugentech Co., Ltd. equipment. The results are shown in Table 1.
[0104] * Common development buffer used in the embodiments of the present invention: pH 7~9, 0.1~1M Tris to Phosphate buffer used, less than 2% surfactant (e.g., tween 20, tween 80, Tergitol TMN, Brij35, Triton X-100, SDS, NP40, etc.), between 0.1~2% protein such as casein, normal serum, albumin, etc., and 10~500 mM NaCl included as the basic composition.
[0105]
[0106] * Gray mark: If cut-off is 30 or lower, it is determined as a false positive or false negative.
[0107] * No color indication: If there is a signal of 30 or more on either the IgM or IgG test line, it is determined to be positive.
[0108] * Sensitivity: Number of positive results / Number of positive samples x 100
[0109] * Specificity: Number of negative judgment results / Number of voice samples x 100
[0110] According to Table 2, when equal amounts of vaccinia virus antigens (L1R, B5R, A27L, A33R) were mixed and used in class capture immunoassay (or indirect immunoassay), the sensitivity was 81.3% (= 26 / 32 x 100) and the specificity was 52.4% (= 11 / 21 x 100). It was found that class capture immunoassay has limitations for use in diagnosing orthofox virus antibodies.
[0112] Example 2: Antigen-antigen pair screening
[0113] We intended to select antigen-antigen pairs suitable for antibody diagnosis of orthofoxvirus using an antigen-antigen sandwich immunoassay. Each of the L1R, B5R, A27L, A33R, and D8L antigens was dotted onto a membrane and conjugated to an Eu bead, and the best antigen-antigen pairs were selected by performing the following procedure.
[0114] 1) Load 0.5 uL of each of the viral antigens L1R, B5R, A27L, A33R, and D8L onto the membrane using a pipette at the same concentration (0.4 mg / mL), and then dry the membrane.
[0115] 2) Each of the viral antigens L1R, B5R, A27L, and A33R is conjugated to a detection bead (gold or fluorescent) to prepare the respective antigen conjugate.
[0116] 3) Mix 5 µL of positive or negative sample with the development buffer, and treat with 0.005 µg of bead-antigen conjugate per test.
[0117] 4) Spread the mixture of sample, buffer, and conjugate on the dried membrane strip with the antigen, and measure the result after 15 minutes using Sugentech Co., Ltd. equipment.
[0118] 5) After calculating the S / N ratio (positive sample result / negative sample result) of 20 combinations of capture and detector for each antigen, the best combination is selected. The results are shown in Figure 1 and Table 3.
[0119]
[0120] * S / N ratio: positive signal / negative signal
[0121] Referring to Figure 1 and Table 3, the B5R-B5R and A33R-A33R pairs were identified as pairs capable of distinguishing between positive and negative with an S / N ratio of 10 or higher.
[0123] Example 3: Determination of whether A33R and B5R antigens are mixed
[0124] To determine whether it is better to use the B5R and A33R antigens selected in Example 2 alone or in combination, the following was performed.
[0125] 1) Load 0.5 uL of each of A33R and B5R onto the membrane using a pipette at the same concentration (0.4 mg / mL), then dry the membrane.
[0126] 2) Prepare each antigen conjugate by conjugating A33R and B5R to a detection bead (gold or fluorescent).
[0127] 3) Mix 5 µL of positive or negative sample with the development buffer, and treat with equal amounts of two types of bead-antigen conjugates, for a total of 0.01 µg per test.
[0128] 4) Spread the mixture of sample, buffer, and conjugate on the dried membrane strip with the antigen, and measure the result using Sugentech equipment after 15 minutes.
[0129] 5) Calculate the S / N ratio (positive sample result / negative sample result) for each condition and select the best combination. The results are shown in Figure 2 and Table 4.
[0130]
[0131] Referring to Figure 2 and Table 4, it was confirmed that the detection signal was generally higher in various positive samples when B5R and A33R antigens were used in combination rather than alone.
[0133] Example 4: Determination of the mixing ratio of A33R and B5R antigens
[0134] To determine the optimal ratio in the membrane line and conjugate, respectively, when mixing A33R and B5R antigens, the following was performed.
[0135] (A) Membrane line
[0136] 1) Prepare A33R and B5R antigens in various weight ratios of 10:0 to 0:10, dispense 1 mg / mL onto a membrane using a pipette, and then dry the membrane.
[0137] 2) A33R and B5R antigens are conjugated to detection beads (gold or fluorescent) to prepare A33R conjugates and B5R conjugates, and these conjugates are mixed in a 1:1 weight ratio and mixed into a development buffer.
[0138] 3) A mixture of the sample, conjugate, and buffer is applied to each membrane strip prepared with the two antigens in a weight ratio of 10:0 to 0:10, and the result is measured using equipment from Sugentech Co., Ltd. after 15 minutes.
[0139] 4) After calculating the S / N ratio (positive sample result / negative sample result) for each condition with a ratio of two antigens of 10:0 to 0:10, the best condition is selected. The results are shown in Figure 3 and Table 5.
[0140] (B) Conjugate
[0141] 1) Mix A33R and B5R antigens in a weight ratio of 1:1, dispense to a total concentration of 1 mg / mL, and then dry the membrane.
[0142] 2) Prepare A33R conjugates and B5R conjugates as described above and mix them in weight ratios of 10:1 to 1:10 to produce a variety of results. For each test, 0.01 µg of total antigen conjugate is mixed with the sample and the development buffer, developed on a strip, and the result is measured using equipment from Sugentech Co., Ltd. after 15 minutes.
[0143] 3) After calculating the S / N ratio (positive sample result / negative sample result) for each condition where the weight ratio of the two conjugates is 10:1 to 1:10, the best condition is selected. The results are shown in Figure 4 and Table 6.
[0144]
[0145]
[0146] Referring to Figures 3 and 4 and Figures 4 and 5, when the A33R:B5R ratio in the line and the conjugate was in the range of 1:9 to 9:1, the detection signal appeared above a certain level, and in particular, when the A33R:B5R ratio was in the range of 5:5 to 2:8, a uniform response was observed.
[0148] Example 5: Clinical Validation (Confirmation of Sensitivity and Specificity)
[0149] To compare the specificity and sensitivity of antibody diagnosis against orthofoxvirus using class capture immunoassay vs. antigen-antigen sandwich immunoassay with the combination of antigens selected in Example 4, the following was performed.
[0150] A33R:B5R was mixed as an antigen in a weight ratio of 1:1, and human serum samples from before (Ab negative) and after (Ab positive) inoculation with the Vaccinia virus were prepared using the Lateral flow immune assay format. Each sample was developed using the capture immunoassay method described in Example 1 and the antigen-antigen sandwich immunoassay method described in Example 4, and the signal was measured using dedicated equipment to confirm the ROC curve. The results are shown in Figures 5 and 6 and Table 7.
[0151] Referring to Figures 5 and 6, compared to the conventional antibody-antigen class capture immunoassay, the antigen-antigen sandwich immunoassay showed improved sensitivity and specificity, and an increased AUC (Area under curve). Referring to Table 7, compared to the class capture immunoassay (Ab-Ag), the antigen-antigen sandwich immunoassay (Ag-Ag) showed improved sensitivity and specificity, and in particular, specificity increased significantly.
[0152]
[0154] Although specific embodiments regarding the orthofoxvirus antigen protein according to the present invention, the composition for diagnosing orthofoxvirus antibodies containing the same, and the apparatus have been described so far, it is obvious that various modifications are possible within the scope of the present invention.
[0155] Therefore, the scope of the present invention should not be limited to the described embodiments, but should be defined by the claims set forth below as well as equivalents thereof.
[0156] That is, the aforementioned embodiments should be understood as exemplary in all respects and not limiting, and the scope of the invention is defined by the claims set forth below rather than by the detailed description, and all modifications or variations derived from the meaning and scope of the claims and equivalent concepts thereof should be interpreted as being included within the scope of the invention.
[0158] <Description of Sequence List>
[0159] Sequence No. 1 is the amino acid sequence of the L1R antigen protein (IMV membrane protein).
[0160] Sequence No. 2 is the amino acid sequence of the D8L antigen protein (IMV membrane protein).
[0161] Sequence No. 3 is the amino acid sequence of the A33R antigen protein (EEV membrane phosphoglycoprotein).
[0162] Sequence No. 4 is the amino acid sequence of the A27L antigen protein (IMV surface protein).
[0163] Sequence No. 5 is the amino acid sequence of the B5R antigen protein (EEV type-I membrane glycoprotein).
Claims
Claim 1 A composition for diagnosing an orthophoxvirus antibody used in an antigen-antigen sandwich immunoassay for antibody diagnosis, wherein the composition comprises an orthophoxvirus antigen protein used as a capture antigen and a detection antigen, wherein the capture antigen and the detection antigen are the same antigen, and the same antigen is an antigen comprising (a) an A33R antigen consisting of the amino acid sequence of SEQ ID NO. 3, (b) a B5R antigen consisting of the amino acid sequence of SEQ ID NO. 5, or (c) an A33R antigen consisting of the amino acid sequence of SEQ ID NO. 3 and a B5R antigen consisting of the amino acid sequence of SEQ ID NO.
5. Claim 2 A composition for diagnosing orthofox virus antibodies according to claim 1, characterized in that the A33R antigen and the B5R antigen are mixed in a weight ratio of 1:9 to 9:
1. Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 A composition for diagnosing orthopox virus antibodies according to claim 1, wherein the orthopox virus is a smallpox virus, a vaccinia virus, or a monkeypox virus. Claim 10 delete Claim 11 An orthofoxvirus antibody diagnostic device comprising a composition according to any one of claims 1, 2 and 9. Claim 12 In claim 11, the device is a diagnostic device for orthofoxvirus antibodies that utilizes antigen-antigen sandwich analysis. Claim 13 In claim 11, the device is an orthofoxvirus antibody diagnostic device comprising a capture antigen immobilized on a solid phase and a detection antigen comprising a detectable label. Claim 14 A device for diagnosing orthofox virus antibodies according to claim 13, wherein the detection antigen comprises any one of a chromogenic enzyme, a luminescent enzyme, a radioactive isotope, a chromophore, a luminescent substance, a fluorescent substance, or a microparticle containing each of these. Claim 15 In claim 11, the device is a device for diagnosing orthofox virus antibodies using a lateral flow immunoassay (LFA), an enzyme-linked immunosorbent assay (ELISA), or a chemiluminescence immunoassay (CLIA). Claim 16 In claim 11, the above-mentioned orthophoxvirus is a smallpox virus, a vaccinia virus, or a monkeypox virus, and the device for diagnosing orthophoxvirus antibodies. Claim 17 A kit for diagnosing orthofoxvirus antibodies comprising a composition according to any one of claims 1, 2 and 9. Claim 18 A method for providing information for diagnosing orthofox virus antibodies, comprising: (a) contacting a biological sample isolated from an individual with a composition according to any one of claims 1, 2 and 9; and (b) confirming an antigen-antibody reaction between the composition and the antibody in the biological sample. Claim 19 A method for providing information for diagnosing an orthofox virus antibody according to claim 18, wherein in step (b) above, a part of the antibody reacts with a capture antigen and another part of the antibody reacts with a detection antigen.
